[go: up one dir, main page]

MX2019003720A - Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. - Google Patents

Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.

Info

Publication number
MX2019003720A
MX2019003720A MX2019003720A MX2019003720A MX2019003720A MX 2019003720 A MX2019003720 A MX 2019003720A MX 2019003720 A MX2019003720 A MX 2019003720A MX 2019003720 A MX2019003720 A MX 2019003720A MX 2019003720 A MX2019003720 A MX 2019003720A
Authority
MX
Mexico
Prior art keywords
disease
parkinson
methods
evil
compositions
Prior art date
Application number
MX2019003720A
Other languages
English (en)
Other versions
MX387961B (es
Inventor
G Salentine Christopher
R Malefyt Thomas
Original Assignee
Biotie Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Inc filed Critical Biotie Therapies Inc
Publication of MX2019003720A publication Critical patent/MX2019003720A/es
Publication of MX387961B publication Critical patent/MX387961B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a comprimidos para administración oral a un sujeto, que comprenden una cantidad terapéuticamente eficaz de SYN120, o una sal farmacéuticamente aceptable de este, en donde el comprimido está sustancialmente libre de lactosa. La presente invención también se refiere a métodos para tratar enfermedades o afecciones que incluyen el mal de Alzheimer y/o la enfermedad de Parkinson, que comprenden administrarle a un paciente que lo necesite comprimidos referentes a estas.
MX2019003720A 2016-09-30 2017-09-29 Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. MX387961B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402357P 2016-09-30 2016-09-30
PCT/US2017/054473 WO2018064559A1 (en) 2016-09-30 2017-09-29 Compositions and methods for treating alzheimer's disease and parkinson's disease

Publications (2)

Publication Number Publication Date
MX2019003720A true MX2019003720A (es) 2019-09-19
MX387961B MX387961B (es) 2025-03-19

Family

ID=61756894

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003720A MX387961B (es) 2016-09-30 2017-09-29 Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX2021014093A MX2021014093A (es) 2016-09-30 2019-03-29 Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014093A MX2021014093A (es) 2016-09-30 2019-03-29 Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.

Country Status (10)

Country Link
US (3) US10314798B2 (es)
EP (1) EP3518914A4 (es)
JP (1) JP2019529502A (es)
AR (1) AR109760A1 (es)
AU (2) AU2017337053B2 (es)
CA (1) CA3037059A1 (es)
IL (1) IL265656A (es)
MX (2) MX387961B (es)
TW (1) TWI753952B (es)
WO (1) WO2018064559A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529502A (ja) 2016-09-30 2019-10-17 バイオティー セラピーズ インコーポレイテッド アルツハイマー病及びパーキンソン病を処置するための組成物及び方法
WO2021089580A1 (en) * 2019-11-04 2021-05-14 Cinclus Pharma Ag Oral formulation of x842

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305606T3 (es) * 1999-04-06 2008-11-01 Sepracor Inc. Succinato de o-desmetilvenlafaxina.
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
DK1831159T3 (da) * 2004-12-21 2010-03-22 Hoffmann La Roche Tetralin og indanderivater samt anvendelser deraf
CA2653758A1 (en) * 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
FR2974102B1 (fr) * 2011-04-13 2014-08-22 Rhodia Operations Composition polyamide stabilisee
WO2015173133A1 (en) * 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
JP2019529502A (ja) 2016-09-30 2019-10-17 バイオティー セラピーズ インコーポレイテッド アルツハイマー病及びパーキンソン病を処置するための組成物及び方法

Also Published As

Publication number Publication date
US10314798B2 (en) 2019-06-11
AU2017337053A1 (en) 2019-04-04
US10973784B2 (en) 2021-04-13
MX387961B (es) 2025-03-19
CA3037059A1 (en) 2018-04-05
AU2017337053B2 (en) 2021-09-02
TWI753952B (zh) 2022-02-01
JP2019529502A (ja) 2019-10-17
EP3518914A1 (en) 2019-08-07
AU2021277698A1 (en) 2021-12-23
US20190142771A1 (en) 2019-05-16
MX2021014093A (es) 2021-12-10
US20180092868A1 (en) 2018-04-05
IL265656A (en) 2019-05-30
EP3518914A4 (en) 2020-06-10
AR109760A1 (es) 2019-01-23
US20210177783A1 (en) 2021-06-17
TW201813638A (zh) 2018-04-16
WO2018064559A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
NZ630589A (en) Methods of treating alzheimer’s disease and pharmaceutical compositions thereof
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MY196869A (en) Cancer treatment combinations
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
AR119159A1 (es) Tratamientos de angioedema
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний
EA202092756A1 (ru) Конденсированные бициклические соединения для применения в качестве ингибиторов убиквитин-специфической пептидазы 30